ECG

InfoBionic Rebrands Company Name to ‘InfoBionic.Ai’, Reinforcing Focus on AI-Enabled ECG

Retrieved on: 
Wednesday, April 10, 2024
Technology, Medical Devices, Health Technology, Telemedicine, Virtual Medicine, Cardiology, Software, Other Health, General Health, Health, Artificial Intelligence, Intelligence, ARC, Machine learning, Mayo Clinic, FDA, Heart, ECG, AI, Medical device

InfoBionic has always been dedicated to remaining at the cutting edge of patient care.

Key Points: 
  • InfoBionic has always been dedicated to remaining at the cutting edge of patient care.
  • Since the organization’s inception in 2015, AI and machine learning have been an integral part of InfoBionic’s remote cardiac telemetry offering.
  • In reality, this name change is just formalizing what we have already become,” says Stuart Long, CEO of InfoBionic.Ai.
  • “Our commitment to evolving remote cardiac telemetry monitoring through existing and novel AI-enabled ECG remains steadfast and unwavering.

HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias

Retrieved on: 
Tuesday, April 9, 2024
Technology, Medical Devices, Health Technology, Cardiology, Software, Biotechnology, Health, Data Management, Artificial Intelligence, Algorithm, Atrial flutter, Intelligence, Patient, Doctor of Philosophy, MD, Arrhythmia, Vectorcardiography, FDA, VCG, ECG, Medical device

This marks the first scientific presentation on the company’s deep learning algorithm, HeartBeam AI.

Key Points: 
  • This marks the first scientific presentation on the company’s deep learning algorithm, HeartBeam AI.
  • The technology is designed to be used in HeartBeam’s small, portable, patient-friendly devices that allow for remote cardiac monitoring.
  • HeartBeam believes this presents a unique opportunity to create a comprehensive repository of data that could unlock personalized AI-driven insights to improve cardiac care.
  • “As we continue to expand our artificial intelligence capabilities, we look forward to demonstrating how the combination of our data rich 3D VECG platform with HeartBeam AI has the potential to transform how cardiac health is managed in the future.”

United States Cardiovascular Devices Market, Size, Share, Forecast 2024-2030 Featuring Abbott Laboratories, Boston Scientific, Edwards Lifesciences, Cardinal Health, Medtronic, GE, J&J, & Siemens - ResearchAndMarkets.com

Retrieved on: 
Monday, April 8, 2024
Health, Medical Devices, Cardiology, Hospital, Cardiac catheterization, Disease, American Heart Association, Stent, Cardiovascular disease, Coronary artery disease, Prevalence, Biotechnology, CVD, ECG, Incidence, Diabetes, Electrocardiography, Public, Research, Mortality, Insight, Death, Risk, Arrhythmia, Diagnosis, Heart failure, CAD, Medical device

Consequently, producers are investing in innovation and developing new cardiovascular devices to satisfy growing healthcare wishes, expanding the increase in the United States cardiovascular devices market.

Key Points: 
  • Consequently, producers are investing in innovation and developing new cardiovascular devices to satisfy growing healthcare wishes, expanding the increase in the United States cardiovascular devices market.
  • Technology is pivotal in employing growth in the United States cardiovascular devices market.
  • Numerous market players actively enforce strategic tasks, propelling an increase in the United States cardiovascular devices market.
  • In the United States cardiovascular devices market, diagnostics and monitoring devices have a significant presence
    The United States cardiovascular device market is broken up by device type into Diagnostics and Monitoring Devices and Therapeutic and Surgical Devices.

SHL Telemedicine’s SmartHeart® Technology Triumphs in US Army Project Convergence – Capstone 4 Experiment

Retrieved on: 
Monday, April 8, 2024
Cardiology, Telemedicine, Virtual Medicine, Defense, Military, General Health, Health, Medical Devices, Health Technology, Mojave Desert, Trauma, Telehealth, Military medicine, SHL, Fortification, Nursing, Physician, ECG

One key event during the experiment was a comprehensive multi-day army medical experiment held at Fort Irwin’s National Training Center in the Mojave Desert amidst the challenging terrains of California’s Tiefort Mountains.

Key Points: 
  • One key event during the experiment was a comprehensive multi-day army medical experiment held at Fort Irwin’s National Training Center in the Mojave Desert amidst the challenging terrains of California’s Tiefort Mountains.
  • PC-C4, a joint, multinational experiment hosted by the U.S. Army across multiple locations in February and March allowed military medicine to explore and integrate the latest technological innovations in a field environment.
  • SmartHeart’s inclusion in this prestigious experiment underscores the growing recognition of SHL’s portable ECG technology as a game-changer in the fast-paced and demanding field of military healthcare.
  • It addresses a crucial need in the continuum of military medical care from initial non-battle evaluation to trauma response, to advanced interventions for intensive and continual care.

First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis

Retrieved on: 
Friday, March 22, 2024
PET/CT, Contract research organization, Biotechnology, Sarcoidosis, Disease, Patient safety, Patient, Tablet, Spirometry, Messenger, Quality of life, Biology, Royal, Fibrosis, Clinical trial, European, Arrest, Safety, Pharmacokinetics, MOC, Phase, KITE, FDA, FVC, ECG, Granuloma, Pharmaceutical industry

The world's first administration of the chitotriosidase 1 (CHIT1) inhibitor (or placebo) to patient took place at the Royal Infirmary in Edinburgh.

Key Points: 
  • The world's first administration of the chitotriosidase 1 (CHIT1) inhibitor (or placebo) to patient took place at the Royal Infirmary in Edinburgh.
  • As part of the trial, patients will take a daily fixed dose of 25 mg OATD-01 or placebo tablets for 12 weeks.
  • Patient safety will be monitored regularly through laboratory tests, neurological examinations and ECG and spirometry.
  • The study will involve approximately 20-30 centres in the US, the European Union, Norway and the UK.

Smartaly and Ambiq Develop Energy Efficient AI-Enabled Medical-Grade ECG Monitor

Retrieved on: 
Tuesday, March 19, 2024
SOC, Partnership, Business, Patient, Animal husbandry, Electronics, Hospital, Pet, SPOT, ECG, Medical device

With more than 99% accuracy, the ECG can notify the users of any abnormality or disturbance in real time for immediate response.

Key Points: 
  • With more than 99% accuracy, the ECG can notify the users of any abnormality or disturbance in real time for immediate response.
  • The Smartaly ECG is lightweight and can last one year on standby mode.
  • "We are very proud to have taken on this global challenge of providing the medical sector with a portable, battery-powered electrocardiogram (ECG) monitor," says Arnaud Duclap, CEO of Smartaly.
  • Helping medical devices overcome their power constraints to provide insightful health analysis that patients can depend on is exactly what we envision with the Smartaly ECG Monitor."

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against iRhythm, Hut 8, and Amplitude and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 15, 2024
Bitcoin, Research, Amplitude, Zio, Bankruptcy, Boston Scientific, J. P. Morgan, Growth, Acceleration, Atrial fibrillation, COVID-19, Patient, Subpoena duces tecum, Defendant, Stroke, News, Data mining, DOJ, Heart failure, Hut 8, P.C, Justice, Marketing, FDA, IRTC, ECG, Mergers and acquisitions, Cryptocurrency

The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.

Key Points: 
  • The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.
  • The Zio XT is intended for non-critical patients, as it does not provide real-time reporting.
  • These types of heart monitors that are approved for high-risk patients and provide near real-time alerts are also referred to as “real-time” monitors.
  • As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.

Viz.ai® Announces Three New Studies Supporting Viz HCM™ Module for the Detection and Management of Suspected Hypertrophic Cardiomyopathy

Retrieved on: 
Wednesday, April 3, 2024
Health, Technology, Hospitals, Health Technology, Software, Artificial Intelligence, Cardiology, Deep learning, FACC, Harvard Medical School, Machine learning, Cone Health Women's Hospital, PPV, Innovation, Algorithm, Artificiality, Assistant, Disease, Associate, Patient, Atlantic Health System, Triage, Salem Hospital, AI, Viz, American College, Massachusetts General Hospital, HCM, Hospital, Hypertrophic cardiomyopathy, Senior counsel, Sports cardiology, Hypertrophy, Medical director, Probability, FDA, ACC, ECG, Mass, Medical imaging

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in cardiology care.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in cardiology care.
  • The Viz HCM module is the first and only AI algorithm cleared by the FDA for HCM.
  • The study found that Viz HCM performance in suspected HCM detection was consistent across various racial backgrounds with a sensitivity of 68.4% and specificity of 99.1%.
  • This validates the effectiveness of relevance score sorting for prioritizing higher probability HCM-positive patients identified by deep-learning algorithms analyzing ECG data.

HeartBeam Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 20, 2024
Cardiology, Software, Health, Artificial Intelligence, Medical Devices, Health Technology, Technology, Clinical Trials, Element, Research, Microsoft, Algorithm, Arrhythmia, Apple, Communication, Patent, Webcast, Patient, Lead, Consultant, Artificial intelligence, G&A, AI, United States patent law, Doctor of Philosophy, Deep learning, Abstract, FDA, ECG, Medical device

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the fourth quarter and full year ended December 31, 2023.
  • Research and development expenses for the fourth quarter of 2023 were $2.0 million, compared to $1.6 million for the fourth quarter of 2022.
  • General and administrative expenses for the fourth quarter of 2023 were $2.1 million compared to $2.1 million for the fourth quarter of 2022.
  • Net loss for the fourth quarter of 2023 was $3.9 million, compared to a net loss of $3.7 million for the fourth quarter of 2022, and $14.6 million for the full year 2023 compared to $13.0 million in the same period of 2022.

AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Medical Devices, Health, Pharmaceutical, Health Insurance, Diabetes, Blood pressure, Depression, Arrhythmia, Hypokalemia, ICS, Anaphylaxis, Angioedema, Congress, Moyamoya disease, AstraZeneca, MAOI, Hyperthyroidism, Risk, ECG, Incidence, Headache, Immunosuppression, Patient, QT interval, Chronic obstructive pulmonary disease, Inhalation, Chickenpox, Research, Budesonide, System, Liver, Cough, Rash, Infection, Salbutamol, Water, Cataract, Adrenal gland, Measles, Safety, Bronchospasm, COPD, Glaucoma, Use, Catherine Disher, Fatality, Monoamine oxidase inhibitor, Hypertension, Medicine, Pharmaceutical industry

AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.

Key Points: 
  • AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.
  • We remain dedicated to addressing the need for affordability of our medicines, but the system is complex and we cannot do it alone.
  • The Company will continue to provide discounts and rebates off the list price to help patients afford its inhaled respiratory medicines.
  • AstraZeneca remains dedicated to transforming patient outcomes, while ensuring access and affordability of our innovative medicines.